Evidence map›Paper›PMID 8394815›Full record

Trial reportEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology1993

Safety and efficacy of lomefloxacin versus norfloxacin in the treatment of complicated urinary tract infections.

I M Hoepelman, W H Havinga, R A Benne, M Zwinkels, M A de Wit, H A de Hond, T A Boon, M R Visser, F W van Asbeck, J Verhoef

Abstract readClinical TrialComparative StudyRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 1993. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.3field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

I M HoepelmanDepartment of Internal Medicine, University Hospital, GA Utrecht, The Netherlands.
W H Havinga
R A Benne
M Zwinkels
M A de Wit
H A de Hond
T A Boon
M R Visser
F W van Asbeck
J Verhoef
Utrecht University · NLDe Hoogstraat Revalidatie · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Seventy patients with complicated urinary tract infections were treated with either lomefloxacin (400 mg once daily) or norfloxacin (400 mg twice daily) for 10 to 14 days. A total of 19 (86%) of 22 patients treated with lomefloxacin and 20 (74%) of 27 patients treated with norfloxacin were cured, as defined by a negative culture five to nine days after completion of therapy (p = 0.09). After four to six weeks, the figures were 56% for lomefloxacin and 48% for norfloxacin. Adverse effects in the lomefloxacin group were observed on 20 occasions in 12 patients (one stopped treatment) compared to nine occasions in five patients treated with norfloxacin (difference not significant).

Indexed as

FluoroquinolonesAdolescentAdultAgedAged, 80 and overAnti-Infective AgentsFemaleHumansMaleMiddle AgedNorfloxacinQuinolonesTreatment OutcomeUrinary Tract InfectionsUrineAnti-Infective AgentsFluoroquinoloneslomefloxacinNorfloxacinQuinolones

Identifiers

PMID8394815
OpenAlexW2040952691

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.